An update from Renalytix AI (RNLX) is now available.
Renalytix plc has appointed Joel R. Jung as the Interim Chief Financial Officer following O. James Sterling’s resignation. Jung’s compensation includes a $8,000 monthly base salary and options for 60,000 company shares. These options will vest partially in August 2024, with the remainder vesting monthly over nine months, and accelerate if a change in control occurs. The Consulting Agreement facilitating this arrangement allows for termination with three months’ notice.
Find detailed analytics on RNLX stock on TipRanks’ Stock Analysis page.
